Literature DB >> 1322047

Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation.

J J Choo1, M A Horan, R A Little, N J Rothwell.   

Abstract

The potent anabolic effects of the beta 2-adrenoceptor agonist clenbuterol on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors. In the present study clenbuterol, presented to rats in the diet (4 mg/kg), caused significant increases in gastrocnemius muscle mass, protein, and RNA content and a decrease in epididymal fat pad mass. These effects were not mimicked by oral administration of the beta 2-adrenoceptor agonist salbutamol even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg/kg diet). However, the selective beta 2-antagonist ICI-118,551 (200 mg/kg diet) reversed the anabolic effects of clenbuterol, and a high dose of DL-propranolol (1,000 mg/kg diet) also inhibited these actions of clenbuterol. Furthermore, continuous infusion of salbutamol (1.15 mg.kg body wt-1.day-1) via miniosmotic pumps did cause significant increases in muscle mass, protein, and RNA content. These results indicate that the anabolic effects of clenbuterol are dependent on interaction with the beta 2-adrenoceptor. However, a long duration of action appears to be required to induce the anabolic effects of beta 2-agonists.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322047     DOI: 10.1152/ajpendo.1992.263.1.E50

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  29 in total

Review 1.  Athletes and doping: effects of drugs on the respiratory system.

Authors:  P N Dekhuijzen; H A Machiels; L M Heunks; H F van der Heijden; R H van Balkom
Journal:  Thorax       Date:  1999-11       Impact factor: 9.139

Review 2.  An Abductive Inference Approach to Assess the Performance-Enhancing Effects of Drugs Included on the World Anti-Doping Agency Prohibited List.

Authors:  Andreas Breenfeldt Andersen; Glenn A Jacobson; Jacob Bejder; Dino Premilovac; Stephen M Richards; Jon J Rasmussen; Søren Jessen; Morten Hostrup
Journal:  Sports Med       Date:  2021-04-02       Impact factor: 11.136

Review 3.  Alternative drugs of abuse.

Authors:  M E Sutter; J Chenoweth; T E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

4.  Short term salbutamol ingestion and supramaximal exercise in healthy women.

Authors:  B Le Panse; A Arlettaz; H Portier; A-M Lecoq; J De Ceaurriz; K Collomp
Journal:  Br J Sports Med       Date:  2006-05-10       Impact factor: 13.800

5.  Case of low dose clenbuterol toxicity.

Authors:  Michael Waight; William McGuinness
Journal:  BMJ Case Rep       Date:  2016-04-15

6.  Role of cyclic AMP sensor Epac1 in masseter muscle hypertrophy and myosin heavy chain transition induced by β2-adrenoceptor stimulation.

Authors:  Yoshiki Ohnuki; Daisuke Umeki; Yasumasa Mototani; Huiling Jin; Wenqian Cai; Kouichi Shiozawa; Kenji Suita; Yasutake Saeki; Takayuki Fujita; Yoshihiro Ishikawa; Satoshi Okumura
Journal:  J Physiol       Date:  2014-10-24       Impact factor: 5.182

7.  Clenbuterol has a greater influence on untrained than on previously trained skeletal muscle in rats.

Authors:  R J Murphy; L Béliveau; K L Seburn; P F Gardiner
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

8.  The regulation of total creatine content in a myoblast cell line.

Authors:  J E Odoom; G J Kemp; G K Radda
Journal:  Mol Cell Biochem       Date:  1996-05-24       Impact factor: 3.396

9.  Therapeutic clenbuterol treatment does not alter Ca2+ sensitivity of permeabilized fast muscle fibres from exercise trained or untrained horses.

Authors:  David R Plant; Charles F Kearns; Kenneth H McKeever; Gordon S Lynch
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

10.  Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation.

Authors:  G Patrick Daubert; Vincent H Mabasa; Vivian W Y Leung; Cynthia Aaron
Journal:  J Med Toxicol       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.